Literature DB >> 32360184

Commonly Used Adjuvant Human Vaccines: Advantages and Side Effects.

Raul Villarreal1, Thomas B Casale2.   

Abstract

Vaccines are a cost-effective and successful means for preventing disease. Routine health vaccine administration begins in early childhood and extends into the elderly; however, there is evidence to suggest that the immunologic and protective response to vaccination is less potent in older individuals. In recent years, newer adjuvant vaccines have been developed to improve humoral and cell-mediated immune response after vaccination. Despite the use of adjuvants in vaccines for many decades, there is limited teaching in postgraduate medical education regarding the adjuvants found in human vaccines. We summarize the current literature cited in PubMed from January 1980 to December 2019. Studies examined included those supporting the use of adjuvants in human vaccines, the mechanisms via which they enhance the immunologic response, and the reported side effects that are associated with the use of adjuvant vaccines. Overall, the data show that newer adjuvant vaccines lead to improved humoral and cell-mediated immunity against infections in populations, including those with decreased response to typical vaccines without adjuvants. Side effects related to adjuvants in vaccines were reported. Research aimed at improving vaccine effectiveness and minimizing side effects continues to be underway.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant; Cell-mediated immunity; Humoral immunity; Innate immunity; Vaccine

Mesh:

Substances:

Year:  2020        PMID: 32360184     DOI: 10.1016/j.jaip.2020.04.045

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  4 in total

1.  Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens.

Authors:  Jin-Tao Zou; Hai-Ming Jing; Yue Yuan; Lang-Huan Lei; Zhi-Fu Chen; Qiang Gou; Qing-Shan Xiong; Xiao-Li Zhang; Zhuo Zhao; Xiao-Kai Zhang; Hao Zeng; Quan-Ming Zou; Jin-Yong Zhang
Journal:  PLoS Pathog       Date:  2021-07-21       Impact factor: 6.823

Review 2.  New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.

Authors:  Takehiro Ura; Akio Yamashita; Nobuhisa Mizuki; Kenji Okuda; Masaru Shimada
Journal:  Vaccine       Date:  2020-11-24       Impact factor: 3.641

Review 3.  Vaccination and immunotherapies in neuroimmunological diseases.

Authors:  Alexander Winkelmann; Micha Loebermann; Michael Barnett; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2022-04-06       Impact factor: 44.711

4.  Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection.

Authors:  Fumi Sato-Kaneko; Shiyin Yao; Fitzgerald S Lao; Jason Nan; Jonathan Shpigelman; Annette Cheng; Tetsuya Saito; Karen Messer; Minya Pu; Nikunj M Shukla; Howard B Cottam; Michael Chan; Anthony J Molina; Maripat Corr; Tomoko Hayashi; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.